Abstract
Rev-erbs are members of the nuclear receptor (NR) transcription factor superfamily and are widely expressed, but are most prevalent in liver, adipose tissue, skeletal muscle and brain. Rev-erbs are key regulators of the circadian rhythm and are expressed in a circadian manner. The discovery that Rev-erbs are ligand-regulated receptors, whose repressive activity is regulated by the endogenous porphyrin ligand, heme, as well as the recent report of the first synthetic Rev-erb ligand, GSK4112/SR6452, suggests that pharmacological modulation through Rev-erb may provide new routes to treat metabolic diseases. Here, we review the work leading to the discovery that Rev-erbs are indeed ligand-regulated and the role that both natural and synthetic Rev-erb ligands have on adipogenesis.
Keywords: Nuclear receptor, heme, GSK4112, SR6452, adipogenesis, metabolism, diabetes, obesity
Current Pharmaceutical Design
Title: A Role for Rev-erbα Ligands in the Regulation of Adipogenesis
Volume: 17 Issue: 4
Author(s): Douglas J. Kojetin and Thomas P. Burris
Affiliation:
Keywords: Nuclear receptor, heme, GSK4112, SR6452, adipogenesis, metabolism, diabetes, obesity
Abstract: Rev-erbs are members of the nuclear receptor (NR) transcription factor superfamily and are widely expressed, but are most prevalent in liver, adipose tissue, skeletal muscle and brain. Rev-erbs are key regulators of the circadian rhythm and are expressed in a circadian manner. The discovery that Rev-erbs are ligand-regulated receptors, whose repressive activity is regulated by the endogenous porphyrin ligand, heme, as well as the recent report of the first synthetic Rev-erb ligand, GSK4112/SR6452, suggests that pharmacological modulation through Rev-erb may provide new routes to treat metabolic diseases. Here, we review the work leading to the discovery that Rev-erbs are indeed ligand-regulated and the role that both natural and synthetic Rev-erb ligands have on adipogenesis.
Export Options
About this article
Cite this article as:
J. Kojetin Douglas and P. Burris Thomas, A Role for Rev-erbα Ligands in the Regulation of Adipogenesis, Current Pharmaceutical Design 2011; 17 (4) . https://dx.doi.org/10.2174/138161211795164211
DOI https://dx.doi.org/10.2174/138161211795164211 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Scorpion Extracts Inhibit Tumor Growth in Esophageal Cancer and Lung Adenocarcinoma
Current Signal Transduction Therapy Mimicking Microvascular Alterations of Human Diabetic Retinopathy: A Challenge for the Mouse Models
Current Medicinal Chemistry Coronary Angiography Using Noninvasive Imaging Techniques of Cardiac CT and MRI
Current Cardiology Reviews Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Ambulatory Blood Pressure and Diabetes: Targeting Nondipping
Current Diabetes Reviews The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Current Neuropharmacology On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design New Insight into Diabetes Management: From Glycemic Index to Dietary Insulin Index
Current Diabetes Reviews Synthesis and Antiproliferative Activity of New Polyoxo 2-Benzyl-2,3- dihydrobenzofurans and Their Related Compounds
Letters in Drug Design & Discovery Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Novel Nano Drug Systems for Cardiovascular Applications
Recent Patents on Biomedical Engineering (Discontinued) Anabolic-androgenic Steroid use and Psychopathology in Athletes. A Systematic Review
Current Neuropharmacology Quorum Sensing Inhibitors from the Sea: Lessons from Marine Symbiotic Relationships
Current Organic Chemistry Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science A SELDI-TOF-MS Study in Lacunar Stroke with Subsequent Haptoglobin Phenotyping
Current Neurovascular Research The Metabolic Syndrome and Cardiovascular Risk
Current Diabetes Reviews